SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Windlas Biotech - Quaterly Results

22 May 2025 Evaluate
A fair growth of 18.34% in the revenue at Rs. 2027.05 millions was reported in the March 2025 quarter as compared to Rs. 1712.85 millions during year-ago period.The Company's Net profit for the March 2025 quarter have declined marginally to Rs. 162.85  millions as against Rs. 169.49 millions reported during the corresponding quarter ended.Operating profit for the quarter ended March 2025 rose to 304.89 millions as compared to 263.75 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 2027.05 1712.85 18.34 7598.78 6309.56 20.43 7598.78 6309.56 20.43
Other Income 49.41 44.40 11.28 176.46 134.68 31.02 176.46 134.68 31.02
PBIDT 304.89 263.75 15.60 1117.61 915.70 22.05 1117.61 915.70 22.05
Interest 13.27 2.76 380.80 43.82 11.03 297.28 43.82 11.03 297.28
PBDT 291.62 260.99 11.74 1073.79 904.67 18.69 1073.79 904.67 18.69
Depreciation 83.35 35.36 135.72 279.85 134.44 108.16 279.85 134.44 108.16
PBT 208.27 225.63 -7.69 793.94 770.23 3.08 793.94 770.23 3.08
TAX 45.42 56.14 -19.10 187.45 188.79 -0.71 187.45 188.79 -0.71
Deferred Tax -0.64 10.93 -105.86 4.72 15.35 -69.25 4.72 15.35 -69.25
PAT 162.85 169.49 -3.92 606.49 581.44 4.31 606.49 581.44 4.31
Equity 104.80 103.99 0.78 104.80 103.99 0.78 104.80 103.99 0.78
PBIDTM(%) 15.04 15.40 -2.32 14.71 14.51 1.34 14.71 14.51 1.34

Windlas Biotech Share Price

871.75 5.60 (0.65%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×